Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Neuro-Degenerative Diseases
|
July 17, 2012
Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model
S Flunkert, M Hierzer, T Löffler, et al.
Leukemia
|
November 20, 2015
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling
M Kordes, M Röring, C Heining, et al.
The British Journal of Dermatology
|
June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma
D Westphal, M Garzarolli, M Sergon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
S M Dieter, C Heining, A Agaimy, et al.
ESMO Open
|
July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
M-V Teleanu, C E Heilig, S Pirmann, et al.
ESMO Open
|
November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
C E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open
|
April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma
L Möhrmann, M Werner, M Oleś, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?
D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A Jahn, A Rump, T J Widmann, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Neuro-Degenerative Diseases
|
July 17, 2012
Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model
S Flunkert, M Hierzer, T Löffler, et al.
Leukemia
|
November 20, 2015
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling
M Kordes, M Röring, C Heining, et al.
The British Journal of Dermatology
|
June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma
D Westphal, M Garzarolli, M Sergon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
S M Dieter, C Heining, A Agaimy, et al.
ESMO Open
|
July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
M-V Teleanu, C E Heilig, S Pirmann, et al.
ESMO Open
|
November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
C E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open
|
April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma
L Möhrmann, M Werner, M Oleś, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?
D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A Jahn, A Rump, T J Widmann, et al.
Page
of 5